Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 285-290

  Garratty, George ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY; CHROMIUM 51; IMMUNOGLOBULIN G;

BLOOD TRANSFUSION; CONFERENCE PAPER; ERYTHROCYTE; PRIORITY JOURNAL; SEROLOGY;

EID: 0031821844     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05433.x     Document Type: Conference Paper

References (43)

1. Mollison PL, Engelfriet CP, Contreras M: Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Scientific, 1997.
2. Mollison PL: The clinical significance of red cell alloantibodies (and autoantibodies) in blood transfusion; in Polesky HF, Walker RH (eds): Safety in transfusion practices. Skokie, IL, College of American Pathologists, 1982, pp131-149.
3. Garratty G: Clinical significance and insignificance of antibodies reacting optimally at 37C; in Butch S (ed): Clinically significant and insignificant antibodies. Washington, DC, American Association of Blood Banks, 1979, pp 29-49.
4. Issitt PD: Antibodies reactive at 30 centigrade, room temperature, and below; in Butch S (ed): Clinically significant and insignificant antibodies. Washington, DC, American Association of Blood Banks, 1979, pp 13-28.
5. Garratty G: The significance of IgG on the red cell surface. Trans Med Rev 1987;1:47-57.
6. Garratty G: The clinical significance (and insignificance) of red-cell-bound IgG and complement; in Wallace ME, Levitt JS (eds): Current applications and interpretation of the direct antiglobulin test. Arlington, VA, American Association of Blood Banks, 1988, pp1-24.
7. Garratty G: Factors affecting the pathogenicity of red cell auto- and alloantibodies; in Nance SJ (ed): Immune destruction of red blood cells. Arlington, VA, American Association of Blood Banks, 1989, pp 109-169.
8. 51Cr; in Bell CA (ed): A seminar on immune-medialed cell destruction. Washington, DC, American Association of Blood Banks, 1981, pp 45-69.
9. Garratty G; Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells; in: Clinical significance and serological aspects of transfusion reactions. Washington DC, American Association of Blood Banks, 1982, pp 91-119.
10. Cutbush M, Mollison PL: Relation between characteristics of blood-group antibodies in vitro and associated patterns of red-cell de struction in vivo. Br J Haematol 1958;2:115-137.
11. Mollison PL: Factors determining the relative clinical importance of different blood group antibodies. Br Med Bull 1959;92-98.
12. Giblett ER: Blood group alloantibodies: an assessment of some laboratory practices. Transfusion 1977;17:299-307.
13. Vengelen-Tyler V, ed. Technical manual. 12th ed. Bethesda, Maryland, American Association of Blood Banks, 1996.
14. Judd WJ: Controversies in transfusion medicine. Prewarmed tests: Con. Transfusion 1995;35:271-275.
15. Mallory D: Controversies in transfusion medicine. Prewarmed tests: Pro-why, when, and how - not if. Transfusion 1995;35:268-270.
16. Garratty G: Attack on prewarmed tests - too much hot air? Transfusion 1996;36:192-193.
17. International Committee for Standardization in Hematology: Recommended methods for radioisotope red cell survival studies. Blood 1971:38:378-386.
18. International Committee for Standardization in Hematology: Recommended methods for radioisotope red cell survival studies. Br J Haematol 1980;45:659-666.
19. Moore GL, Peck CC, Sohmer PR, Zuck TF: Some properties of blood stored in anticoagulant CPDA-1 solution. A brief summary. Transfusion 1981;21:135-137.
20. Engelfriet CP, Ouwehand WH: ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies; in Contreras M (ed): Baillière's clinical haematology. London, Baillière Tindall, 1990, pp 321-327.
21. Garratty G: Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Trans Med Rev 1990;IV:297-312.
22. Zupanska B: Cellular immunoassays and their use for predicting the clinical significance of antibodies; in Garratty G (ed): Immunobiology of transfusion medicine. New York, Dekker, 1994, pp 465-491.
23. Hadley AG, Poole J, Arndt P, Garratty G: A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfusion 1995;35:20S (abstract).
24. Arndt P, Garratty G: Measuring interactions of monocytes with IgG sensitized RBCs using flow cytometry.Transfusion 1992;22:21S (abstract).
25. Bratosin D, Mazurier J, Slomianny C, Aminoff D, Montreuil J: Molecular mechanisms of erythrophagocytosis: flow cytometric quantitation of in vitro erythrocyte phagocytosis by macrophages. Cytometry 1997;30:269-274.
26. b in vitro and in vivo: a case study. Immunohematology 1996; 12:11-13.
27. Nance S, Garratty G: Correlations between an in vitro monocyte monolayer assay and autoimmune hemolytic anemia (AIHA). Transfusion 1982;22:410 (abstract).
28. Nance S, Nelson J, O'Neill P, Garratty G: Correlation of monocyte monolayer assays, maternal antibody titers, and clinical course in hemolytic disease of the newborn (HDN). Transfusion 1984;24:415 (abstract).
29. Nance S, Nelson JM, Horenstein J, Arndt PA, Platt LD, Garratty G: Monocyte monolayer assay - an efficient non-invasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 1989;92;89-92.
30. Garratty G, Nance S, O'Neill P. Correlation of monocyte monolayer assays and RBC survival in patients with alloantibodies of questionable clinical significance. Transfusion 1985;25:474 (abstract).
31. Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;127:449-452.
32. 51Chromium red cell survival study. Transfusion 1988;28:265-267.
33. Garratty G, Arndt P, Nance S: The potential clinical significance of blood group alloantibodies to high frequency antigens. Blood 1997;90:473a (abstract).
34. b as scssed by flow cytometry. Immunohematology 1997;13:93-96.
35. a demonstrating a change in its clinical significance. Vox Sang 1988;55:171-175.
36. 51Cr red cell survival of serologically incompatible red cell units. Transfusion 1985;25:34-38.
37. Garratty G, Arndt P, Nance S: IgG subclass of blood group alloantibodies to high frequency antigens. Transfusion 1996;36:50S (abstract).
38. a (Yta) and Gerbich antibodies. Transfusion 1979;19:650 (abstract).
39. a. Transfusion 1979;19:609-610.
40. Panzer S, Mueller-Eckhardt G, Salama A, Strauss BE, Kiefel V, Muelier-Eckhardt C; The clinical significance of HLA antigens on red cells.Transfusion 1984;24:486-489.
41. Panzer S, Mayr WR, Graninger W, Püchler K, Höcker, Lechner K: Haemolytic transfusion reactions due to HLA antibodies. The Lancet 1987; 1:474-477.
42. Molthan L: Biological significance of the York, Cost, McCoy and Knops alloantibodies. Blood Transfusion and Immunohaematology 1982;XXV:127-147.
43. Mudad R, Rao N, Issitt PD, Roy RB, Combs MR, Telen MJ: JMH variants: serologic, clinical, and biochemical analyses in two cases. Transfusion 1995;35:925-930